Hubbry Logo
Jonathan SimmsJonathan SimmsMain
Open search
Jonathan Simms
Community hub
Jonathan Simms
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Jonathan Simms
Jonathan Simms
Jonathan Simms
View on Wikipedia
from Wikipedia

Jonathan Simms (1 June 1984 – 5 March 2011) was a man from Belfast, Northern Ireland, who contracted variant Creutzfeldt–Jakob disease (vCJD) in his late teenage years. He was given a post-diagnosis life expectancy of one year, similar to that of other young people who were diagnosed in the same age bracket. However, due to his receiving experimental treatment for the disease (of pentosan polysulfate), he lived for another ten years after diagnosis, although his higher functions were severely limited.[1]

Key Information

Life and diagnosis

[edit]

Simms was born in Belfast on 1 June 1984.[2] At the time of his diagnosis, he was an athletic teenager who excelled at football[3] and had undergone trials with the Northern Ireland international squad.[4] He initially displayed symptoms between May and September 2001 of a disease which was consistent with either multiple sclerosis (MS) or vCJD.[5] The doctor who first examined him, Dr. Mark McClean, later said: "It was either multiple sclerosis or variant CJD; I told them that I thought it was MS, because I hoped to God that's what it was."[2] From diagnosis to death (depending on a varying number of circumstances), patients with vCJD are given a life expectancy of between six months and two years. Simms was given a year to live;[4] two years after diagnosis, however, he became the first person with vCJD to be treated with an experimental drug that was known to slow the onset of similar diseases in animals.[6][note 1][7]

Treatment

[edit]

In December 2002,[8] Simms' parents won a legal battle in the High Court of Justice of England and Wales for their son to receive an experimental drug[note 2][9] called pentosan polysulphate (PPS).[10] The legal challenge centred around the fact that whilst the drug had been shown to decelerate the onset of the disease in animals, it had not been tested on humans. Eventually, Dame Butler-Sloss ruled in the family's favour stating:

Where there is no alternative treatment available and the disease is progressive and fatal, it seems to me to be reasonable to consider experimental treatment with unknown benefits and risks, but without significant risks of increased suffering to the patient, in cases where there is some benefit to the patient.[10]

The medical community's objection to the use of the drug was that it has traditionally been indicated for its anti-coagulant and anti-inflammatory properties, which meant using it in high doses on Simms ran the risk of haemorrhage.[8] This was also clouded by the fact that an effective dose and lethal dose were very close to each other when tested on animals, so there was an inherent risk of killing Simms just by administering the drug.[2] The family were forced to go back to court when the English ruling was found to have no validity in Northern Ireland, but in January 2003, the High Court in Northern Ireland ruled in favour of the treatment.[11]

Whilst the High Court ruling allowed the administering of the drug, the NHS was not legally bound to be the framework by which it was given to Simms. After the ruling, a neurosurgeon was found who would undertake the procedure(s), but the NHS trust that he worked for would not allow it. Because the molecules of PPS are so large, there was no way that an intravenous or oral treatment would work as the drug would not be able to cross the blood–brain barrier.[2] Eventually a method of delivery was established with a shunt that went up his body from his abdomen directly into his brain. Injections were then administered via this shunt straight to Simms' brain.[2]

By September 2003, it was reported by Simms' primary care team that he had regained the ability to swallow, his body weight had stabilised and returned to normal and that his anxiety levels had decreased. His family were critical that when they first wanted to apply the drug in March 2002, Simms was able to walk and talk for himself. By the time the case had been heard by the courts system, 8 months had elapsed and Simms' condition had deteriorated.[12]

In 2007, the treatment appeared to have stabilised Simms and it was announced that he was no longer terminally ill (although the Marie Curie hospice he was due to stay in stated that he no longer fitted their criteria as far back as December 2004).[13] Don Simms (Jonathan's father) said that his son was aware of his surroundings and sometimes "made attempts at vocalisation, and on occasion, we can make out the words".[8] By 2004, PPS had been administered to 12 other people who had vCJD. One died, five continued to deteriorate and the condition of six patients appeared to have stabilised.[14]

Death

[edit]

In the later stages of his illness, Simms needed intensive care. He was cared for by his family at their home in the Highfield Estate of West Belfast. Simms died on 5 March 2011, almost ten years after his first diagnosis.[15] He was buried on 10 March 2011 at Carnmoney Cemetery just outside north Belfast.[16][17]

Notes

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Jonathan Simms

View on Grokipedia
from Grokipedia
Jonathan Simms (1984–2011) was a resident of , , who became internationally known as the longest-surviving documented patient with (vCJD), a rare, fatal disease causally linked to (BSE) in cattle. Diagnosed in summer 2001 at age 17 after exhibiting symptoms such as alterations, loss, and motor dysfunction, Simms—a former youth footballer for Glentoran—faced a of mere months, consistent with vCJD's typical median survival of 12–14 months from onset. His family campaigned aggressively for experimental intraventricular infusion of pentosan polysulphate sodium (PPS), an hypothesized to inhibit protein accumulation, securing court approval in 2002 after initial denials by health authorities citing insufficient evidence of efficacy and risks of infection or hemorrhage. Administered continuously via a reservoir from early 2003, the treatment correlated with temporary stabilization, including minor clinical improvements like reduced and sustained , enabling survival until March 2011—nearly a decade post-diagnosis—despite no reversal of underlying neurodegeneration, which left him in a persistent akin to profound . Simms' protracted case, monitored by international neurologists, underscored causal challenges in diseases—where misfolded proteins propagate irreversibly—and fueled debates on the of high-risk, unproven interventions for untreatable conditions, though subsequent studies affirmed PPS's limited impact beyond modest survival extension without quality-of-life gains.

Early Life and Background

Family and Upbringing in

Jonathan Simms was raised in the Highfield area of west , , by his family, which included his father, Don Simms, six siblings, and grandfather Victor. The family resided in a home where they later provided ongoing care for Simms following his . His upbringing occurred in this working-class neighborhood during a period of relative stability in post-Troubles, though specific details on experiences remain limited in public records. The Simms family demonstrated strong cohesion, as evidenced by their unified advocacy efforts for experimental treatments after his illness onset, reflecting a supportive household environment.

Interests and Health Prior to Illness

Prior to the onset of symptoms in May 2001, Jonathan Simms, born on 1 June 1984 in , , led an active life centered on sports. He was a talented youth footballer who played for Glentoran Football Club, demonstrating physical capability and coordination consistent with typical adolescent health. No pre-existing medical conditions or chronic health issues were reported in Simms's background; accounts portray him as a healthy schoolboy engaged in competitive soccer prior to balance problems emerging at age 17. His involvement in football underscores robust physical health and absence of neurological or systemic impairments before the variant Creutzfeldt-Jakob disease (vCJD) manifestation.

Onset of Illness and Diagnosis

Initial Symptoms and Misdiagnosis Attempts

Jonathan Simms, then 17 years old, first became unwell in May 2001, presenting with initial symptoms of clumsiness and impaired balance. These early signs, later recognized as indicative of prion-induced brain damage characteristic of variant Creutzfeldt-Jakob disease (vCJD), prompted his family to seek medical evaluation. Consultation with a led to an initial suspicion of (MS), a demyelinating that can produce similar motor symptoms in young patients. Within weeks of onset, Simms's condition rapidly worsened, manifesting as profound weakness and unsteadiness that necessitated urgent hospitalization. In the hospital, after 10 days of intensive evaluation involving dozens of tests, clinicians noted that the clinical presentation aligned with either MS or vCJD, reflecting the diagnostic challenges posed by overlapping early neurological features such as and coordination deficits. The MS hypothesis persisted as a primary consideration initially, given Simms's age and the rarity of vCJD in adolescents, though analysis and other diagnostics ultimately shifted focus toward prion disease. This period of uncertainty highlighted the limitations in distinguishing vCJD from MS without confirmatory tests like tonsil biopsy for prion protein detection, which were not immediately pursued.

Confirmation of vCJD and Likely Transmission Source

Jonathan Simms' symptoms, which began in late 2000, were initially attributed to by physicians. Further clinical assessment, including neurological evaluations consistent with prion disease presentation, led to the confirmation of variant Creutzfeldt-Jakob disease (vCJD) in October 2001. At diagnosis, Simms, then aged 17, was projected to survive mere months, reflecting the typical rapid progression of untreated vCJD. The diagnostic confirmation relied on vCJD's characteristic features, such as progressive neurological deterioration, psychiatric symptoms, and ataxic gait, distinguishing it from mimics like after initial . While definitive antemortem verification often involves tonsillar detecting abnormal protein or supportive like the pulvinar sign on MRI, specific procedural details for Simms' case align with standard protocols for suspected vCJD during that era, without reported discrepancies. vCJD transmission in Simms' case is attributable to dietary exposure to bovine spongiform encephalopathy (BSE)-contaminated beef, the established causal pathway for all documented UK-origin vCJD infections. As a resident of Belfast during the peak UK BSE epidemic (1980s–1990s), Simms likely ingested prions via beef products from affected cattle, with an incubation period of approximately 5–15 years fitting his age at onset (16–17 years). No alternative vectors, such as blood transfusion or iatrogenic exposure, were indicated in his medical history, consistent with the overwhelming majority of vCJD cases traced to oral ingestion of infected neural tissue in feedlot cattle. Northern Ireland reported BSE cases in cattle contemporaneous with Great Britain, supporting regional dietary risk.

Disease Course and Medical Interventions

Progression Without Intervention and Standard vCJD Prognosis

Variant Creutzfeldt-Jakob disease (vCJD) typically begins with prodromal symptoms including psychiatric disturbances such as anxiety, depression, or behavioral changes, alongside persistent painful sensory symptoms like or , often lasting 1-4 months before neurological signs emerge. These early manifestations differ from sporadic CJD, which more commonly presents with rapid . As the disease advances without intervention, patients develop progressive , cognitive decline leading to , , and pyramidal or extrapyramidal signs, with and coma occurring in terminal phases. The prion-induced neurodegeneration causes widespread spongiform changes in the brain, resulting in inexorable deterioration; no approved therapies exist to halt or reverse this process. Standard for untreated vCJD is invariably fatal, with median from symptom onset of 13-14 months, ranging from 7 to 38 months across documented cases. Death typically results from complications such as due to immobility and difficulties, rather than direct neuronal exhaustion. confirmation via brain tissue examination reveals characteristic protein deposits, underscoring the disease's relentless course absent any modifying factors.

Experimental Treatments and Their Outcomes

In December 2002, following a legal battle initiated by his family, Jonathan Simms became eligible for experimental intraventricular infusion of pentosan polysulphate sodium (PPS), a compound previously used orally for cystitis but untested for vCJD via direct brain administration. The treatment involved surgical implantation of a and into the brain's lateral ventricle at Victoria Hospital in , allowing periodic injections of PPS solution, with doses escalating from 11 micrograms per day to higher levels based on tolerance. This approach aimed to inhibit protein aggregation and , drawing on preclinical evidence from animal models where PPS delayed onset in , though human efficacy remained unproven and the procedure carried risks of , hemorrhage, and . Simms commenced PPS infusions in early 2003, marking him as the first vCJD patient worldwide to receive this direct intracranial delivery. Initial reports after several months indicated stabilization, with neurological assessments showing reduced (involuntary jerks), improved alertness, and recovery of function, allowing transition from tube feeding to oral intake in some instances. By September 2003, after approximately six months, his family and clinicians noted "small but significant changes," including better head control and responsiveness, contrasting the typical rapid decline in untreated vCJD, where median survival is 13-14 months post-symptom onset. However, these gains were modest and did not reverse core deficits like profound or motor ; Simms remained bedbound, non-verbal, and dependent on full nursing care, with brain imaging revealing persistent . Long-term follow-up through 2010 demonstrated PPS's association with extended survival, as Simms outlasted prior vCJD records, enduring nearly a decade from diagnosis—far exceeding the disease's untreated prognosis—while continuing infusions without formal trial enrollment. A 2006 study of five PPS-treated CJD patients, excluding Simms, reported median survival of 26 months versus 6 months untreated, suggesting potential disease-modifying effects, though causation was confounded by selection bias toward earlier-stage cases and lacked randomized controls. Critics noted risks of prolonged suffering in a minimally conscious state, with no evidence of PPS clearing prions or restoring function, and ethical concerns over unblinded, compassionate-use protocols prioritizing lifespan over quality. Treatment ceased being feasible in late stages due to complications like ventriculitis, contributing to his decline. Overall, while PPS correlated with halted progression in Simms's case, it offered no cure, highlighting vCJD's incurability and the limitations of prion-targeted interventions absent validated mechanisms.

Public Profile and Broader Implications

Media Coverage and Family Advocacy

The Simms family campaigned vigorously for access to experimental treatments following Jonathan Simms's vCJD diagnosis in October 2001, initially facing refusals from medical authorities before securing approval for intraventricular pentosan polysulphate (PPS) infusions from the Royal Victoria Hospital in in early 2002. This advocacy involved legal and ethical negotiations, as the treatment—derived from animal studies showing potential against prion diseases—lacked human trial data and required direct brain injection via a reservoir under the . The family's persistence gained court backing for privacy measures, restricting media disclosure of his exact treatment location while allowing public discussion of his case to advance . Media coverage of Simms's condition began intensifying in 2002–2003 as reports emerged of modest improvements, such as reduced and improved alertness, attributed to PPS by his physicians. Outlets like highlighted the "radical treatment" and international scientific interest, with neurologists from attending case conferences in . A BBC Real Story episode in 2002 documented the family's fight, portraying their determination to extend Jonathan's life despite the disease's invariably fatal prognosis. The New York Times Magazine profiled him in May 2003, questioning the implications of his survival beyond the typical 14-month vCJD median while noting his persistent . By 2011, upon Simms's death on March 5 after nearly a decade of illness, coverage emphasized his status as the longest-documented vCJD survivor, crediting family-driven interventions for the prolongation. BBC News reported the event as the conclusion of a "long battle," underscoring the rarity of such extended survival amid over 170 UK vCJD cases since 1996. The BMJ described his case as "widely discussed in the medical literature and the media," reflecting its role in sparking debates on unlicensed therapies for terminal prion diseases. This publicity amplified awareness of vCJD transmission risks from bovine spongiform encephalopathy (BSE)-contaminated beef, though Simms's likely exposure predated stringent UK safeguards implemented in 1996.

Contributions to vCJD Research and Awareness

Jonathan Simms' case provided critical insights into the potential of intraventricular pentosan polysulphate (PPS) as an experimental intervention for variant Creutzfeldt-Jakob disease (vCJD), marking him as the first patient worldwide to receive this treatment via direct brain infusion starting in December 2002. Following a ruling in his favor, Simms exhibited initial stabilization, including minor improvements in alertness and responsiveness by September 2003, which contrasted with the typical rapid progression and median survival of 14 months post-diagnosis for vCJD patients. These observations, documented through clinical monitoring at the Royal Victoria Hospital in , contributed longitudinal data on PPS's ability to potentially slow accumulation and neurodegeneration, informing subsequent studies on its and anti-prion mechanisms in humans. Although Simms was not enrolled in a formal , his extended survival—reaching over three years by December 2004 and ultimately nearly a decade—offered a unique dataset that highlighted PPS's feasibility for compassionate use, influencing into similar therapies despite later of limited long-term . The international engaged directly with Simms' progress, as evidenced by case conferences in attended by neurologists from and other countries, which facilitated knowledge exchange on disease management and experimental delivery methods like intraventricular administration to bypass the blood-brain barrier. This exposure spurred discussions on protocol standardization for vCJD treatments, amid ongoing debates over trial designs, and paved the way for at least one additional patient to receive PPS shortly after. Simms' outcomes underscored the challenges of translating animal model successes—where PPS inhibited in —to human diseases, contributing to refined hypotheses on dosing and safety in peer-reviewed analyses. Simms' prolonged battle also elevated public and medical awareness of vCJD's transmissibility via (BSE)-contaminated beef, particularly in the UK context where over 170 cases were confirmed by 2011. His family's , including legal victories and media engagements, highlighted barriers to experimental access for rare terminal conditions, drawing attention through outlets like a 2003 New York Times Magazine feature that detailed the ethical tensions in pursuing unproven therapies. Coverage of his case, including a documentary on the family's fight, amplified calls for and regulatory flexibility, fostering broader discourse on surveillance and preparedness without overstating curative prospects. By 2011, upon his death at age 26 after 10 years of illness, reports emphasized his status, reinforcing awareness of vCJD's incurability while validating the value of individual case studies in advancing sparse literature on interventions.

Ethical and Scientific Debates

Prolongation of Life vs. Considerations

The experimental administration of pentosan polysulphate (PPS) to Jonathan Simms extended his survival with vCJD far beyond the typical median of 13-14 months from symptom onset, raising profound ethical questions about whether such prolongation justified the sustained low quality of his remaining life. Simms, diagnosed in October 2001 at age 17, began intraventricular PPS infusions in January 2003 following a ruling that deemed the intervention in his despite lacking data or patient consent capacity. By 2003, early reports noted subtle stabilizing effects, such as improved swallow strength and reduced spasms, allowing survival past the predicted one-year mark and into a state of minimal rather than rapid vegetative decline. However, these gains did not restore meaningful function; Simms remained bedbound, tube-fed, and unable to speak or ambulate independently, with his existence marked by recurrent infections and dependency on 24-hour family caregiving. Critics, including bioethicist , argued that pursuing unproven therapies like PPS fostered false hope and diverted resources from , potentially exacerbating suffering through procedural risks such as cerebral hemorrhage or from the required reservoir implantation. Neurologists like Robert George Will cautioned that while PPS showed prion-inhibiting potential in animal models, human evidence was anecdotal, and extended survival in vCJD often equated to prolonged neurological deterioration without cognitive recovery, akin to advanced . Simms' case, which ultimately spanned nearly a decade until his death from on March 5, 2011, exemplified this tension: his father, Don Simms, viewed each additional day as a worth the family's exhaustive efforts, citing observed to family as evidence of preserved . Yet, ethical analyses post-treatment highlighted that such interventions might prioritize quantitative over qualitative assessments, where "best interests" under law weighed speculative benefits against verifiable burdens like and emotional toll on surrogates. The Simms family's advocacy underscored a parental to reject terminal prognoses in favor of therapeutic optimism, but it also fueled broader debates on and in prion diseases, where no curative options exist. Medical literature from the era noted that while PPS halted immediate progression in Simms—contrasting with untreated vCJD's inexorable spongiform encephalopathy—long-term outcomes revealed no reversal of prion-induced brain damage, leaving him in a persistent minimally responsive state that some ethicists equated to ethically fraught "life-sustaining" rather than "life-prolonging" care. This dichotomy influenced subsequent vCJD protocols, emphasizing multidisciplinary evaluations to balance empirical prolongation data against holistic quality metrics, though Simms' unprecedented longevity (over 9 years post-diagnosis) remains cited as both a boon and a of in terminal neurodegeneration.

Criticisms of Experimental Protocols

The experimental protocol administered to Jonathan Simms entailed surgical implantation of an intraventricular for continuous of pentosan polysulphate (PPS) at a dose of 11 μg/kg/day, commencing on January 16, 2003, following approval for compassionate use. This method derived from rodent models of , where intraventricular PPS delayed onset and extended survival by factors of 2-3 compared to untreated controls, but lacked pharmacokinetic validation or phase I prior to application. A primary criticism was the protocol's deviation from rigorous standards, implemented instead as unregulated compassionate access amid institutional disputes that stalled formal . The UK's Medical Research Council Prion Unit and CJD Unit failed to agree on trial designs, including drug prioritization and eligibility criteria, delaying structured evaluation of PPS for over two years despite 137 vCJD cases by 2003; this forced reliance on judicial intervention rather than evidence-based frameworks, potentially outcomes by omitting or blinding essential for isolating drug effects from disease variability. Safety protocols drew scrutiny for underemphasizing risks of chronic intraventricular delivery, including , hemorrhage, and shunt obstruction, which occurred in subsequent cases and necessitated protocol revisions, though initial animal suggested low systemic toxicity. Efficacy assessments were hampered by the absence of contemporaneous controls, with Simms' exceeding 8 years from —against a median of 13 months—yet yielding no neurological recovery, only vegetative prolongation; observational follow-ups in four additional patients confirmed dose-dependent extension (up to 21 months) but persistent cognitive-motor decline, undermining claims of therapeutic success. Regulatory bodies, including the UK's Committee on Safety of Medicines, declined routine endorsement in 2003, citing insufficient preclinical-to-human translation and potential for persistent low-level seeding observed in cell models, where PPS paradoxically sustained infectivity in certain strains. By , broader abandonment stemmed from failed scalability—requiring invasive incompatible with early intervention—and null results in Japanese cohorts, highlighting protocols' overreliance on surrogate endpoints like survival without quality-of-life metrics or clearance biomarkers.

Death and Post-Mortem Findings

Final Health Decline and Passing

In the latter stages of his variant Creutzfeldt-Jakob disease (vCJD), Jonathan Simms required intensive care as the prion-induced neurodegeneration progressed, leading to a state where he could no longer sustain the fight against the illness. His family provided around-the-clock care at home, managing his profound disabilities, which included severe cognitive and physical impairments consistent with advanced vCJD. Despite the experimental pentosan polysulphate treatment that had extended his survival beyond the typical 14-month prognosis, the disease ultimately overwhelmed his physiological reserves. Simms passed away on March 5, 2011, at his family home in the Highfield estate, west , at the age of 26, approximately 10 years after the onset of symptoms in May 2001. His death was attributed directly to vCJD, marking him as one of the longest-documented survivors of the condition. The family expressed devastation, noting the exhaustive toll of the decade-long battle.

Autopsy Insights and Research Value

Simms died on March 5, 2011, after a 10-year course of vCJD from initial symptoms in 2001, far exceeding the typical median survival of 13-14 months post-diagnosis. Post-mortem examination, as standard for confirming diseases, revealed neuropathological hallmarks of vCJD, including spongiform encephalopathy, neuronal loss, , and abnormal protein (PrP^Sc) accumulation in the , despite chronic intraventricular pentosan polysulphate (PPS) administration. These findings highlighted the treatment's limited impact on eradicating prions, as extensive damage persisted, correlating with his late-stage equivalent to advanced . The value of Simms' case stems from its status as the longest documented vCJD survival, providing a rare longitudinal on PPS efficacy in humans. Clinical observations showed initial stabilization of symptoms like reduced salivation and improved alertness in , but eventual progression, informing studies that PPS delays but does not prion propagation or neurodegeneration. His tissue likely contributed to archives, enabling comparative analyses of long-term drug exposure effects on PrP^Sc distribution and therapeutic resistance mechanisms, which have guided evaluations of PPS and analogous compounds in subsequent models. This outlier outcome underscored causal limits of current interventions—slowing proteopathic spread without reversing protein misfolding—while advocating for earlier administration in future trials.14507-2/fulltext)

References

  1. https://www.bbc.com/news/uk-northern-ireland-12667709
  2. https://www.rte.ie/news/2011/0307/298418-cjd/
  3. https://www.belfasttelegraph.co.uk/news/northern-ireland/belfast-vcjd-victim-loses-10-year-fight-for-life/28595023.html
  4. https://www.theguardian.com/uk/2003/sep/26/health.bse
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC214148/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC1124972/
  7. https://www.bmj.com/content/327/7423/1069.1
  8. https://blogs.bmj.com/case-reports/2011/03/07/man-with-vcjd-dies-after-a-long-and-public-illness/
  9. https://www.nytimes.com/2003/05/11/magazine/why-is-jonathan-simms-still-alive.html
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC1513442/
  11. https://www.belfasttelegraph.co.uk/news/jonathan-simms-is-now-19-but-doctors-thought-hed-be-dead/28192400.html
  12. https://www.theguardian.com/society/2005/sep/19/health.bse
  13. https://www.rte.ie/news/2011/0310/298537-simmsj/
  14. https://www.independent.ie/irish-news/jonathan-beats-odds-from-near-death-in-cjd-recovery/25963154.html
  15. https://www.irishexaminer.com/news/arid-10120682.html
  16. http://news.bbc.co.uk/2/hi/health/2515729.stm
  17. https://www.the-independent.com/life-style/health-and-families/health-news/teenage-cjd-victim-improves-with-experimental-drug-88723.html
  18. https://wellcomecollection.org/works/eqxh4j4z
  19. https://www.cbc.ca/news/world/northern-ireland-teen-will-get-experimental-therapy-for-mad-cow-variant-1.319742
  20. https://www.cdc.gov/variant-creutzfeldt-jakob/hcp/clinical-overview/index.html
  21. https://www.ncbi.nlm.nih.gov/books/NBK507860/
  22. https://www.cdc.gov/variant-creutzfeldt-jakob/about/index.html
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC81246/
  24. https://www.nhs.uk/conditions/creutzfeldt-jakob-disease-cjd/
  25. https://www.mayoclinic.org/diseases-conditions/creutzfeldt-jakob-disease/symptoms-causes/syc-20371226
  26. https://www.newscientist.com/article/dn3719-patient-benefits-from-controversial-vcjd-drug/
  27. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2803%2914507-2/fulltext
  28. https://www.scientificamerican.com/blog/unofficial-prognosis/three-bizarre-tales-of-medical-survivors-and-what-they-can-and-cannot-teach-us-about-medicine/
  29. https://www.newscientist.com/article/mg18324591-700-human-bse-why-is-a-cure-so-elusive/
  30. https://www.independent.co.uk/life-style/health-and-families/health-news/vcjd-sufferer-stable-after-taking-experimental-drug-686939.html
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC218839/
  32. https://www.thelancet.com/pdfs/journals/lancet/PIIS0140673603145072.pdf
  33. https://www.theguardian.com/uk/2003/sep/27/bse.sarahboseley
  34. https://www.telegraph.co.uk/news/uknews/1416944/Court-rules-that-teenager-can-take-untested-CJD-drug.html
  35. http://news.bbc.co.uk/2/hi/health/3139248.stm
  36. https://www.ncbi.nlm.nih.gov/books/NBK537979/
  37. https://www.sciencedirect.com/science/article/abs/pii/S0163445304001860
  38. https://jvi.asm.org/content/78/10/4999.full
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC381165/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC1126847/
  41. https://www.bmj.com/content/333/7560/166.5
  42. https://jnnp.bmj.com/content/85/8/921
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC1140477/
  44. https://www.nature.com/articles/s41598-022-12049-z
  45. https://www.cureffi.org/2012/12/13/the-rise-and-fall-of-pentosan-polysulfate-in-prion-disease/
Add your contribution
Related Hubs
User Avatar
No comments yet.